Markets:

Overview

News

Currencies

International

Treasuries

CinCor Pharma, Inc. - Common Stock (NQ:CINC)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 23, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about CinCor Pharma, Inc. - Common Stock

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

February 21, 2023

From CinCor Pharma Inc

Via GlobeNewswire

There's a Lot to Love About Mineralys' Valentine's Day IPO

February 13, 2023

MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million

Via MarketBeat

Topics Initial Public Offering

These 2 Healthcare Stocks Have Doubled in 2023

February 01, 2023

Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.

Via MarketBeat

CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

January 24, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)

January 20, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

CINCOR PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

January 10, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

January 10, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion

January 09, 2023

CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments

Via Spotlight Growth

CINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CinCor Pharma, Inc. Is Fair to Shareholders

January 09, 2023

From Halper Sadeh LLC

Via Business Wire

CinCor Pharma to be Acquired by AstraZeneca

January 09, 2023

From CinCor Pharma Inc

Via GlobeNewswire

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

November 04, 2022

From CinCor Pharma Inc

Via GlobeNewswire

CinCor Reports Third Quarter Financial Results and Provides Corporate Update

November 03, 2022

From CinCor Pharma Inc

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.